UnitedHealth shares surge about 20% year-to-date as investors weigh execution against ongoing probes

UnitedHealth Group’s stock has climbed roughly 20% year-to-date, a move that has reframed the debate for many investors. A recent market recap noted that the rebound has occurred even as the company remains pressured by regulatory investigations, policy uncertainty, elevated healthcare costs, and higher utilization. The framing in the market discussion is increasingly operational, not headline-driven, with investors looking for steady execution rather than optimistic messaging. The same roundup pointed to a business that has large, diversified revenue streams, but one that still depends on trust from regulators and customers, particularly in Medicare programs and pharmacy services.

In its most recent quarterly update, UnitedHealth reported that the cost pressures it faced earlier in 2026 may be easing at the margin. For first quarter 2026, the company said consolidated revenues were $111.7 billion, and it earned $6.90 per share and $7.23 per share on an adjusted basis. UnitedHealth also reported a medical cost ratio of 83.9% for the quarter, down 90 basis points versus the prior year period. The medical cost ratio, a commonly used insurance metric that compares medical spending to premium revenue, is a key driver of profitability for payers like UnitedHealthcare. The company said its operating cost ratio was 13.8%, and it reiterated an emphasis on technology and efficiency improvements. It further raised its full-year outlook to greater than $17.35 per share (reported) and greater than $18.25 per share (adjusted).

UnitedHealth also highlighted capital returns and additional strategic moves alongside its profitability picture. The first quarter results included an arrangement to repurchase at least $2 billion of common stock, expected to complete by the end of the second quarter of 2026. Management also described continued investments aimed at improving consumer and provider experiences, accelerating modernization, and strengthening cybersecurity and artificial intelligence capabilities. The company’s expanded focus matters for the stock narrative because critics have often argued that UnitedHealth’s scale makes it more sensitive to execution risk, especially when systems and processes become targets for government oversight.

Regulatory and legal pressure has not gone away, however, and it has shown up in multiple lanes. One ongoing flashpoint involves Medicare Advantage, the private-insurance program that pays insurers risk-adjusted amounts for managing seniors and disabled enrollees. In January, Sen. Chuck Grassley released a majority staff report saying UnitedHealth’s record appears to show “gaming” of the risk-adjustment system, based on a review of over 50,000 pages of company documents. The report argued that the company captured more diagnoses and diagnosis codes than other Medicare Advantage organizations, resulting in higher payments from the Centers for Medicare and Medicaid Services. UnitedHealth has said it disagrees with that characterization, and the dispute continues to be an earnings and reputation overhang because risk adjustment directly affects insurer revenue.

A second regulatory concern relates to Medicare participation more broadly. In July 2025, UnitedHealth said it began complying with formal criminal and civil requests from the U.S. Department of Justice after reviewing media reports about investigations into certain aspects of its participation in the Medicare program. The company said it has confidence in its practices, pointed to independent CMS audits, and also described launching third-party reviews of policies and processes for risk assessment coding, managed care practices, and pharmacy services. UnitedHealth cautioned that it cannot predict the outcome of the government investigations, leaving the financial exposure and timing of any resolutions still uncertain.

Beyond Medicare Advantage and coding disputes, the rally discussion also returns to pharmacy, an area where UnitedHealth’s Optum business sits at the center of policy scrutiny. Optum Rx, a pharmacy benefit manager (PBM), announced in May 2026 what it described as a transparent, fee-based pharmacy care model. In plain terms, the new structure is intended to replace traditional arrangements that depend on drug list prices or prescription volume with monthly, clearly defined fees per member that are independent of those variables. Optum Rx said the approach eliminates “spread pricing” and provides transparency into its fees, including payments tied to group purchasing organization arrangements. UnitedHealth’s goal is to make pharmacy pricing more predictable for clients while aligning incentives more directly with plan sponsors and patients.

The stock’s momentum is therefore easy to understand, but it is not risk-free. Many of the most material uncertainties are not scheduled to be resolved on a simple earnings calendar: regulators and courts can take months or years, and the magnitude of any financial impact can vary. The recent market recap also referenced lingering questions tied to the 2024 Change Healthcare cyberattack, including how provider payment bridges were handled during the disruption. UnitedHealth previously described an update process for restoring key Change Healthcare systems and said it launched a temporary funding assistance program for providers impacted by the attack’s payment disruption. Still, the market will likely keep demanding proof that cost trends stay favorable and that business model changes translate into durable margins.

Looking ahead, traders and long-term holders are likely to watch three areas closely. First is whether UnitedHealth can sustain the medical cost improvements reflected in the first quarter’s medical cost ratio trend and its raised earnings outlook. Second is whether government scrutiny around Medicare Advantage risk adjustment and related DOJ activity produces further enforcement, settlements, or policy changes that could affect reimbursement. Third is whether the Optum Rx fee-based pharmacy model gains meaningful uptake and survives further political and regulatory pressure on PBM practices. Until those threads tighten, the appeal of the rally may remain conditional, even as the stock’s early-2026 gains continue to draw attention.